» Articles » PMID: 28974906

Alzheimer's Disease and Osteoporosis

Overview
Journal Tzu Chi Med J
Specialty General Medicine
Date 2017 Oct 5
PMID 28974906
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) and osteoporosis are both common degenerative diseases in the elderly population. The incidence of both diseases increases with age and will be posing enormous societal burden worldwide. It may appear that AD and osteoporosis are two distinct diseases although many risk factors are shared. Previous observational studies have shown that patients with osteoporosis have higher risks of developing AD than those who do not have osteoporosis. Although osteoporosis, falls, and fractures are more often seen in patients with AD than other older adults, the association between these two diseases may be due to a pathophysiological link rather than one condition causing the other. Several and studies lend support to this notion. Patients with AD have excessive amyloid plaques in the brain, and the pathology may extend to peripheral organs and cause skeletal amyloid deposition, which would enhance receptor activator nuclear factor-kappa B ligand signaling and lead to greater osteoclast activities. Patients with osteoporosis may have Vitamin D deficiency or lower levels of Vitamin D binding protein, which protects against amyloid aggregation, thus linking Vitamin D deficiency and AD or osteoporosis and AD. Osteoporosis coexisting with AD provides a window to examine the amyloid hypothesis from peripheral tissues. Future studies are warranted to clarify the role of genetic background regarding Vitamin D levels, exposure to sunlight, estrogen replacement therapy, and physical activity in patients with both chronic diseases.

Citing Articles

Analysis of Preventive Effect of Bisphosphonate for Osteoporotic Fracture in Patients with Alzheimer's Disease and Patient Mortality.

Jang M, Kwon Y, Hwang J, Choi G, Kim M, Lee D J Clin Med. 2025; 14(2).

PMID: 39860306 PMC: 11766000. DOI: 10.3390/jcm14020300.


Unveiling biomarker detection in Alzheimer's disease: a computational approach to microarray analysis.

Khan N, Choudhary S, Ali M, Shawaz M, Lohnes B, Poddar N 3 Biotech. 2024; 14(12):311.

PMID: 39606011 PMC: 11589038. DOI: 10.1007/s13205-024-04159-4.


IL-33 prevents age-related bone loss and memory impairment by suppression of Th17 response: evidence in a d-galactose-induced aging mouse model.

Kaushal S, Parul , Tripathi A, Singh D, Paul A, Alka K JBMR Plus. 2024; 8(10):ziae101.

PMID: 39224568 PMC: 11365962. DOI: 10.1093/jbmrpl/ziae101.


The Brain-Gut-Bone Axis in Neurodegenerative Diseases: Insights, Challenges, and Future Prospects.

Li R, Miao Z, Liu Y, Chen X, Wang H, Su J Adv Sci (Weinh). 2024; 11(38):e2307971.

PMID: 39120490 PMC: 11481201. DOI: 10.1002/advs.202307971.


Amyloid-β neuropathology induces bone loss in male mice by suppressing bone formation and enhancing bone resorption.

Jung Y, Ay B, Cyr S, Tognoni C, Klovdahl K, Matthias J Bone Rep. 2024; 21:101771.

PMID: 38725879 PMC: 11078651. DOI: 10.1016/j.bonr.2024.101771.


References
1.
Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

2.
Depypere H, Vierin A, Weyers S, Sieben A . Alzheimer's disease, apolipoprotein E and hormone replacement therapy. Maturitas. 2016; 94:98-105. DOI: 10.1016/j.maturitas.2016.09.009. View

3.
Loskutova N, Honea R, Vidoni E, Brooks W, Burns J . Bone density and brain atrophy in early Alzheimer's disease. J Alzheimers Dis. 2009; 18(4):777-85. PMC: 2842449. DOI: 10.3233/JAD-2009-1185. View

4.
Law W, Wang W, Moore P, Mollee P, Ng A . Cardiac Amyloid Imaging with 18F-Florbetaben PET: A Pilot Study. J Nucl Med. 2016; 57(11):1733-1739. DOI: 10.2967/jnumed.115.169870. View

5.
Lee J, Bliwise D, Ansari F, Goldstein F, Cellar J, Lah J . Daytime sleepiness and functional impairment in Alzheimer disease. Am J Geriatr Psychiatry. 2007; 15(7):620-6. DOI: 10.1097/JGP.0b013e3180381521. View